Wolfe Research analysts put together the bottom 20% stocks among the Earnings Quality model ranking. This model is designed ...
SAN DIEGO, Nov. 27, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that members of the executive leadership team are scheduled to present and host ...
The Swiss pharma group has agreed a $9 per share deal to acquire Poseida, valuing the company at around $1 billion, with another $500 million potentially payable to shareholders in a contingent value ...
The company's recent appearance at the Frankfurt Equity Forum left many strategic questions unanswered, highlighting the significant challenges Evotec faces in its future strategic positioning. Fresh ...